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Introduction: Minor ABO mismatch occurs when donors possess
pre-existing immunity to recipient ABO antigens. This combination
presents a risk for clonal expansion of donor B lymphocytes targeting
discrepant ABO antigens after allogeneic hematopoietic cell
transplantation (HCT).
Material and Methods: 1594 patients underwent allo-HCT be-
tween January 1986 and June 2010. Recipient age ranged 0-74 (me-
dian 40) years. 47% underwent allo-HCT for acute leukemia, 13%
for NHL/CLL. 72% received myeloablation, while 28% underwent
reduced-intensity conditioning (RIC). Recipient-donor pairs were
61% ABO matched 18% major mismatched (mm), 17% minor
mm, and 4.5% bidirectional mm. 45% of grafts derived from bone
marrow (BM), 55% from peripheral blood (PB). ABO mm distribu-
tion did not differ by age, disease, conditioning, or graft source.
Median follow-up was 5.7 years.
Results: Compared to ABO matched HCT, OS was inferior across
allminormmpairs (medianOS 2 years vs 7.4 years for ABOmatched,
p\0.0001;CoxHR1.3, 95%CI1.1-1.8, p50.003).Minormmpairs
were found to have significantly increased NRM through day 100
(18% vs 13%, p 5 0.02; HR 1.5, 95%CI 1.06-2.05, p 5 0.02). Im-
paired OS predominated in minor mm receiving BM (HR 1.8, 95%
CI 1.3-2.3, p\ 0.0001) compared with PB grafts (HR 1.1, 95%CI
0.8-1.4, p5 0.59). Interestingly, patients transplanted for acute leu-
kemia exhibited the survival impairment (HR 1.3, 95%CI 1.1-1.6, p
5 0.01) whereas those allografted for NHL/CLL did not (HR 1.1,
95%CI 0.6-1.8, p 5 0.8). OS and NRM differences in the minor
mmpairs did not correlate with conditioning regimen or donor relat-
edness. A trend toward increased acute GVHD was observed in mi-
nor mm recipients (HR 1.3, 95%CI 1.0-1.7; p 5 0.08). Since 2005,
replacement of graft plasma has not ameliorated inferior outcomes
in minor mm HCT, suggesting a cellular etiology. Major mm pairs
did not demonstrate impairments in OS or differences in NRM.
Conclusion: Minor ABO mismatch between recipients and donors
is associated with significantly impaired OS and increased NRM fol-
lowing allo-HCT and should be avoided if possible. In particular,
minor mm BM grafts have inferior outcomes, and we hypothesize
the survival deficit is attributable to increased ABO reactive B cell
content in BM compared with PB. The abrogation of survival im-
pairment in minormmNHLpatients may result from peritransplant
use of Rituximab leading to in vivo depletion of these pathogenic
ABO reactive B cells.365
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Allogeneic hematopoietic stem cell transplantation (allo HSCT) is
a curative therapy for patients (pts)withmultiplemyeloma,but conven-
tional allo HSCT has been associated with unacceptably high rates of
mortality. Non-myeloablative allo HSCT has resulted in high rates
of acute and chronic graft-versus-host disease (GvHD) and progres-
sion.We report initial results of a pilot study of 13 pts, usingT-cell de-
pleted alloHSCT (alloTCDHSCT) fromHLA compatible (matched
related8, matched unrelated3, andmismatched unrelated2) donors. All
13 pts had relapsedmyelomawithin 12mos following autoHSCT, and
12/13 pts had high-risk cytogenetics at diagnosis [t(4;14), t(14;16),
del17p byFISHand/or del13qby karyotyping]. All pts achieved at least
a partial response from preceding chemotherapy or second auto
HSCT. Pts underwent allo TCD HSCT with busulfan (0.8mg/kg x
10 doses), melphalan (70mg/m2 x 2 days), fludarabine (25mg/m2 x 5
days) and rabbit ATG (2.5mg/kg x 2 days). T-cell depletion was per-
formed by positive CD34 selection (Isolex) followed by rosetting
with sheep erythrocytes, achieving\ 103CD3+/kg for all grafts. Allpts engrafted promptly (median d+11, range d+10 to +12). Pts were el-
igible toreceive lowdosesofdonor lymphocyte infusions (DLI) (5x10e5
– 1x10e6 CD3+/kg) no earlier than 5mos post alloHSCT. Five pts are
in continuous complete remission (CR) at 28, 22, 12, 10 and 9mos fol-
lowing allo TCD HSCT. Two of these pts reentered CR following
DLI.Twoptshad stableminimal residual disease for 26 and24mosbe-
fore progression and are being treated with DLI at the current time.
Twopts with refractorymyeloma,whowere transplantedwith residual
16%and10%plasmacells inmarrow,were inCR for 12and8mospost
allo TCD HSCT, developed progression of disease and recently re-
ceivedDLI. 12/13ptswerewithout signsofGvHD,but onepthadpos-
sible superimposed gut GvHD following fulminant C diff colitis. Four
pts died, incl one at 2 mos with oseltamivir-resistant H1N1 infection;
one at 4 mos due to respiratory failure secondary to infection of un-
known etiology, one at 5 mos due to status epilepticus, and one at 6
mos due to acute cerebral hemorrhage.
We are now performing a phase II clinical trial at MSKCC for pts
with relapsed multiple myeloma following auto SCT who had high-
risk cytogenetics at diagnosis or at relapse as well as upfront allo
HSCT for pts with high-risk cytogenetics at diagnosis following
preceding auto SCT.366
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We evaluated a photodepletion technique to selectively deplete
graft-versus-host disease (GVHD) alloreacting T cells from stem cell
transplants. Donor lymphocytes were stimulated with irradiated in-
vitro expanded recipientT lymphocytes.AlloactivatedTcells preferen-
tially retaining the photosensitizer 4, 5-dibromorhodamine 123
(TH9402) (Kiadis Pharma, NL) were eliminated by light exposure.
Twenty-four patients with hematological malignancies (16 high-risk)
conditioned with fludarabine, cyclophosphamide and total body,
irradiation received a CD34-selected stem cell allograft from an HLA
identical sibling and 5x106/kg selectively depleted (SD) donor T cells.
Low-dose cyclosporine was used as the only post-transplant immuno-
suppression. The overall probability of grade III-IV a-GVHD was
13%. Fourteen patients developed chronic GVHD (c-GVHD). Five
patients relapsed, 2 of whom remain alive in remission after further
treatment. Thirteen patients survive at a median of 22months. Overall
survival and disease free survival probabilities (+/2 SEM) were 43 +/2
13%and 35 +/2 13% respectively. TheSD technique resulted in a low
incidence of relapse (24 +/2 10%), butwas complicated by late non-re-
lapsemortality associated with c-GVHD and infection of 50 +/2 14%
at 4 years follow up. These results suggest that SD may effectively re-
duce severe a-GVHD while conserving graft-versus leukemia effects,
but the depletion strategy has yet to be optimized.367
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Double unit cord blood transplantation (DCBT) is a frequent
strategy to augment graft cell dose. However, in the majority of
